RareSearch logo

Arcarios NV

50+ personnel
Headquartered in Chandler
Established in 2025
Website

About

Description

Arcarios is a drug development company dedicated to the discovery and development of innovative products in the field of bone and joint diseases such as osteoporosis and osteoarthritis. Current treatment options are insufficient and indicate an urgent need for disease modifying drugs. The company’s proprietary technology platform allows for the successful development of treatments focussed on restoring cartilage and bone, thereby addressing an important unmet medical need in today’s society. Having two advanced therapeutic programs with a strong technology and IP position, Arcarios is well positioned to capitalize on the market opportunity in the field of osteoarthritis and osteoporosis.

Services

  • Life Cycle Assessment (LCA)

    Analyze the lifecycles of products and services with regard to their environmental impacts.

  • Viral Vector Production

    Produce viral vectors for gene therapy and vaccine development.

  • Data Visualization

    Visualize data collected from clinical trials and/or clinical research.

  • Emerging Market Opportunities

    Analyze risks and opportunities in new markets for patient access to new treatments.

  • Adverse Event Reporting

    Monitor and report adverse events related to drug products in clinical trials.

See more

Organization members

  • Amanda Lee

    Communications Director

  • William Kim

    Data Analyst

  • Laura Martinez

    Clinical Trials Coordinator

  • Michael Brown

    Executive Director

  • Robert Garcia

    Fundraising Director

  • Emily Davis

    Research Scientist

Case Studies

https://loremflickr.com/640/480/nature?lock=3757893123833856

Gene Therapy for Alkaptonuria

This project aims to develop gene therapy treatments for Alkaptonuria through collaboration between researchers and patient advocacy groups.
https://loremflickr.com/640/480/nature?lock=2908955246329856

Health Technology Assessment for Mucopolysaccharidosis (MPS)

This project involves conducting a Health Technology Assessment (HTA) for new treatments targeting Mucopolysaccharidosis, a group of rare metabolic disorders.
https://loremflickr.com/640/480/nature?lock=5897205292466176

Clinical Trial Design for Fibrodysplasia Ossificans Progressiva (FOP)

This project focuses on designing clinical trials for Fibrodysplasia Ossificans Progressiva, a rare and debilitating condition that causes soft tissues to turn into bone.
https://loremflickr.com/640/480/nature?lock=3258702530347008

Biomarker Development for Gaucher Disease

This project aims to develop novel biomarkers for Gaucher Disease to improve diagnosis and monitoring.
https://loremflickr.com/640/480/nature?lock=3366903980490752

Orphan Drug Designation for Niemann-Pick Disease

This project seeks to obtain orphan drug designation for a new treatment for Niemann-Pick Disease, a rare and fatal genetic disorder.
See more